Hemophilia Drugs Market Report

Global and Region Hemophilia Drugs Market Demand & Opportunity Outlook 2022-2028

  • POSTDATE：Jul 29, 2022
  • PAGES：162
  • REPORT CODE：GMM886405
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • The hemophilia treatment drugs market is experiencing entry of a large number of new drugs in the market. Few of them have already arrived and other long lasting clotting factors and more promising drugs are on their way to get launched in this market. For instance, follow up data from phase I/II study of hemophilia medicine ‘Emicizumab’ by Roche has demonstrated promising results regarding safety and prophylactic efficiency in people with severe hemophilia A. Another example is of ‘Eloctate’ for type A and ‘Aprolix’ for type B hemophilia, respectively. These two newly arrived biogen products are opposed to commonly prescribe course of three infusions per week as they are longer-acting than traditional treatments and require only one to two infusions per week, due to their new mechanism of action.

    With increasing attention on prophylactic treatment, the market for hemophilia drugs is estimated to have a positive outlook over the coming years. The prophylactic treatment approach prevents spontaneous bleeding episodes, significantly improves the quality of life in terms of physical activities, and maintains the level of clotting factors above a baseline. According to the studies conducted by the US National Library of Medicine determined that the savings on prophylactic treatment be approximately USD 8,312 to USD 17,675 per bleeding episode in a person. Moreover, this line of treatment reduces joint damage and suffering from pain. Several of such long-acting therapeutics are under development and expected to be launched over the next four years. The shift in preference for prophylactic treatment due to its advantages will drive this market’s growth over the forecast period.The Americas led the global hemophilia drugs market in 2017 and is expected to continue its dominance until the end of 2023. The Americas have the highest revenue share in the global market with the US contributing to the majority of this revenue. Several countries in the region have introduced health care reforms which are having a positive impact on the market growth. Moreover, healthcare reforms in the US have also helped reduce the cost of pharmaceutical drugs, increased access to healthcare, and improved the overall quality of healthcare. These healthcare reforms are likely to have a positive impact on healthcare insurance and also reduce hospital stay and overall medical expenses, which will boost this market’s growth in the region.

    The report details the trend, potential and market size of Hemophilia Drugs market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.

    The first part (Chapter1-7) mainly covers the qualitative analysis of Hemophilia Drugsmarket, defines the market attractiveness level of Hemophilia Drugs market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.

    The second part (Chapter8-12), based on the segmentation of Hemophilia Drugs industry, describes the types of Hemophilia Drugs market, the applications of major players and the market size, and deeply analyzes the current situation of the global Hemophilia Drugs market and the development prospects and opportunities of Hemophilia Drugs industry.

    The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.

    As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global Hemophilia Drugs market in Chapter 13.

    By Player:

    • Sangamo Biosciences

    • Dimension Therapeutics

    • Grifols

    • F Hoffmann-La Roche

    • Alnylam Pharmaceuticals

    • Catalyst Biosciences

    • BioMarin

    • Octapharma

    • Bayer

    • Swedish Orphan Biovitrum

    • Baxalta

    • Pfizer

    • Spark Therapeutics

    • CSL Behring

    By Type:

    • Hemophilia A

    • Inhibitors

    • Hemophilia B

    • Von Willebrand Disease

    By End-User:

    • Recombinant Therapies

    • Plasma-Derived Therapies

    By Geography:

    • United States

    • Europe

    • China

    • Japan

    • India

    • South Korea

  • TABLE OF CONTENT

    1 Introduction

    • 1.1 Market Definition

    • 1.2 Market Segment Analysis

    • 1.3 Market Size 2022

    • 1.4 Hemophilia Drugs Market Outlook: Forecast for 2022 - 2028

    • 1.5 Pricing Analysis

    2 Executive Summary

    3 Hemophilia Drugs Market Lineage Outlook

    • 3.1 Parent Market Outlook

    • 3.2 Related/Ancillary Market Outlook

    • 3.3 Penetration & Growth Prospect Mapping, 2022

    4 Market Analysis Tools: Porter's Five Forces

    • 4.1 Supplier Power

    • 4.2 Buyer Power

    • 4.3 Substitution Threat

    • 4.4 Threat of New Entrants

    • 4.5 Competitive Rivalry

    5 Hemophilia Drugs Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)

    • 5.1 Political/Legal Landscape

    • 5.2 Economic Landscape

    • 5.3 Social Landscape

    • 5.4 Technology Landscape

    6 Hemophilia Drugs Market - Value Chain Analysis

    • 6.1 Industry's Value Chain Analysis

    • 6.2 Product Life Cycle

    • 6.3 User Perspective Analysis

    7 Region and Country-wise Hemophilia Drugs Market Analysis and Outlook to 2022

    • 7.1 Global Hemophilia Drugs Consumption (2017-2022)

    • 7.2 United States Hemophilia Drugs Consumption (2017-2022)

    • 7.3 Europe Hemophilia Drugs Consumption (2017-2022)

    • 7.4 China Hemophilia Drugs Consumption (2017-2022)

    • 7.5 Japan Hemophilia Drugs Consumption (2017-2022)

    • 7.6 India Hemophilia Drugs Consumption (2017-2022)

    • 7.7 South Korea Hemophilia Drugs Consumption (2017-2022)

    8 Region and Country-wise Hemophilia Drugs Market Analysis and Outlook to 2028

    • 8.1 Global Hemophilia Drugs Consumption Forecast (2022-2028)

    • 8.2 United States Hemophilia Drugs Consumption Forecast (2022-2028)

    • 8.3 Europe Hemophilia Drugs Consumption Forecast (2022-2028)

    • 8.4 China Hemophilia Drugs Consumption Forecast (2022-2028)

    • 8.5 Japan Hemophilia Drugs Consumption Forecast (2022-2028)

    • 8.6 India Hemophilia Drugs Consumption Forecast (2022-2028)

    • 8.7 South Korea Hemophilia Drugs Consumption Forecast (2022-2028)

    9 Global Hemophilia Drugs Market Outlook by Types and Applications to 2022

    • 9.1 Global Hemophilia Drugs Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global Hemophilia A Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global Inhibitors Consumption and Growth Rate (2017-2022)

      • 9.1.3 Global Hemophilia B Consumption and Growth Rate (2017-2022)

      • 9.1.4 Global Von Willebrand Disease Consumption and Growth Rate (2017-2022)

    • 9.2 Global Hemophilia Drugs Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Recombinant Therapies Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Plasma-Derived Therapies Consumption and Growth Rate (2017-2022)

    10 Global Hemophilia Drugs Market Outlook by Types and Applications to 2028

    • 10.1 Global Hemophilia Drugs Consumption Forecast and Growth Rate by Type (2022-2028)

      • 10.1.1 Global Hemophilia A Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.2 Global Inhibitors Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.3 Global Hemophilia B Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.4 Global Von Willebrand Disease Consumption Forecast and Growth Rate (2022-2028)

    • 10.2 Global Hemophilia Drugs Consumption Forecast and Growth Rate by Application (2022-2028)

      • 10.2.1 Global Recombinant Therapies Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.2 Global Plasma-Derived Therapies Consumption Forecast and Growth Rate (2022-2028)

    11 Global Hemophilia Drugs Import and Export Analysis (Top 5 Countries)

    • 11.1 Global Hemophilia Drugs Import by Region (Top 5 Countries) (2017-2028)

    • 11.2 Global Hemophilia Drugs Export by Region (Top 5 Countries) (2017-2028)

    12 Coronavirus Disease (COVID-19) Impact

    • 12.1 Industry Impact Analysis

    • 12.2 Hemophilia Drugs Market Outlook to 2028 - COVID-19 Affected Forecasts

    13 Competition Matrix

    • 13.1 Target Markets

    • 13.2 Comprehensive Analysis of Products in Competitive Markets

    14 Global Hemophilia Drugs Market Competitive Analysis

    • 14.1 Sangamo Biosciences

      • 14.1.1 Sangamo Biosciences Company Details

      • 14.1.2 Sangamo Biosciences Hemophilia Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.1.3 Sangamo Biosciences Hemophilia Drugs Product and Service

    • 14.2 Dimension Therapeutics

      • 14.2.1 Dimension Therapeutics Company Details

      • 14.2.2 Dimension Therapeutics Hemophilia Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.2.3 Dimension Therapeutics Hemophilia Drugs Product and Service

    • 14.3 Grifols

      • 14.3.1 Grifols Company Details

      • 14.3.2 Grifols Hemophilia Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.3.3 Grifols Hemophilia Drugs Product and Service

    • 14.4 F Hoffmann-La Roche

      • 14.4.1 F Hoffmann-La Roche Company Details

      • 14.4.2 F Hoffmann-La Roche Hemophilia Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.4.3 F Hoffmann-La Roche Hemophilia Drugs Product and Service

    • 14.5 Alnylam Pharmaceuticals

      • 14.5.1 Alnylam Pharmaceuticals Company Details

      • 14.5.2 Alnylam Pharmaceuticals Hemophilia Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.5.3 Alnylam Pharmaceuticals Hemophilia Drugs Product and Service

    • 14.6 Catalyst Biosciences

      • 14.6.1 Catalyst Biosciences Company Details

      • 14.6.2 Catalyst Biosciences Hemophilia Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.6.3 Catalyst Biosciences Hemophilia Drugs Product and Service

    • 14.7 BioMarin

      • 14.7.1 BioMarin Company Details

      • 14.7.2 BioMarin Hemophilia Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.7.3 BioMarin Hemophilia Drugs Product and Service

    • 14.8 Octapharma

      • 14.8.1 Octapharma Company Details

      • 14.8.2 Octapharma Hemophilia Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.8.3 Octapharma Hemophilia Drugs Product and Service

    • 14.9 Bayer

      • 14.9.1 Bayer Company Details

      • 14.9.2 Bayer Hemophilia Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.9.3 Bayer Hemophilia Drugs Product and Service

    • 14.10 Swedish Orphan Biovitrum

      • 14.10.1 Swedish Orphan Biovitrum Company Details

      • 14.10.2 Swedish Orphan Biovitrum Hemophilia Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.10.3 Swedish Orphan Biovitrum Hemophilia Drugs Product and Service

    • 14.11 Baxalta

      • 14.11.1 Baxalta Company Details

      • 14.11.2 Baxalta Hemophilia Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.11.3 Baxalta Hemophilia Drugs Product and Service

    • 14.12 Pfizer

      • 14.12.1 Pfizer Company Details

      • 14.12.2 Pfizer Hemophilia Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.12.3 Pfizer Hemophilia Drugs Product and Service

    • 14.13 Spark Therapeutics

      • 14.13.1 Spark Therapeutics Company Details

      • 14.13.2 Spark Therapeutics Hemophilia Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.13.3 Spark Therapeutics Hemophilia Drugs Product and Service

    • 14.14 CSL Behring

      • 14.14.1 CSL Behring Company Details

      • 14.14.2 CSL Behring Hemophilia Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.14.3 CSL Behring Hemophilia Drugs Product and Service

    15 Appendix


    TABLE OF CHARTS

    • Table Definition of Hemophilia Drugs

    • Figure Hemophilia Drugs Picture

    • Table Global Hemophilia Drugs Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Hemophilia Drugs Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Hemophilia Drugs Market: Year-over-year Growth 2022 - 2028 (%)

    • Table Parent Market Analysis

    • Figure Parent Market Price

    • Table Related/Ancillary Market Outlook Analysis

    • Table Supplier Power Analysis

    • Table Buyer Power Analysis

    • Table Substitution Threat Analysis

    • Table Threat of New Entrants Analysis

    • Table Competitive Rivalry Analysis

    • Figure Global Hemophilia Drugs Consumption by Country (2017-2022)

    • Figure United States Hemophilia Drugs Consumption and Growth Rate (2017-2022)

    • Table Europe Hemophilia Drugs Consumption and Growth Rate (2017-2022)

    • Figure China Hemophilia Drugs Consumption and Growth Rate (2017-2022)

    • Figure Japan Hemophilia Drugs Consumption and Growth Rate (2017-2022)

    • Figure India Hemophilia Drugs Consumption and Growth Rate (2017-2022)

    • Figure South Korea Hemophilia Drugs Consumption and Growth Rate (2017-2022)

    • Figure Global Hemophilia Drugs Consumption Forecast by Country (2022-2028)

    • Figure United States Hemophilia Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe Hemophilia Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure China Hemophilia Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan Hemophilia Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure India Hemophilia Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea Hemophilia Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Hemophilia A Consumption and Growth Rate (2017-2022)

    • Figure Global Inhibitors Consumption and Growth Rate (2017-2022)

    • Figure Global Hemophilia B Consumption and Growth Rate (2017-2022)

    • Figure Global Von Willebrand Disease Consumption and Growth Rate (2017-2022)

    • Figure Global Recombinant Therapies Consumption and Growth Rate (2017-2022)

    • Figure Global Plasma-Derived Therapies Consumption and Growth Rate (2017-2022)

    • Figure Global Hemophilia A Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Inhibitors Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Hemophilia B Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Von Willebrand Disease Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Recombinant Therapies Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Plasma-Derived Therapies Consumption Forecast and Growth Rate (2022-2028)

    • Table Global Hemophilia Drugs Import by Region (Top 5 Countries) (2017-2028)

    • Table Global Hemophilia Drugs Export by Region (Top 5 Countries) (2017-2028)

    • Table Sangamo Biosciences (Foundation Year, Company Profile and etc.)

    • Table Sangamo Biosciences Hemophilia Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Sangamo Biosciences Hemophilia Drugs Product and Service

    • Table Dimension Therapeutics (Foundation Year, Company Profile and etc.)

    • Table Dimension Therapeutics Hemophilia Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Dimension Therapeutics Hemophilia Drugs Product and Service

    • Table Grifols (Foundation Year, Company Profile and etc.)

    • Table Grifols Hemophilia Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Grifols Hemophilia Drugs Product and Service

    • Table F Hoffmann-La Roche (Foundation Year, Company Profile and etc.)

    • Table F Hoffmann-La Roche Hemophilia Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table F Hoffmann-La Roche Hemophilia Drugs Product and Service

    • Table Alnylam Pharmaceuticals (Foundation Year, Company Profile and etc.)

    • Table Alnylam Pharmaceuticals Hemophilia Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Alnylam Pharmaceuticals Hemophilia Drugs Product and Service

    • Table Catalyst Biosciences (Foundation Year, Company Profile and etc.)

    • Table Catalyst Biosciences Hemophilia Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Catalyst Biosciences Hemophilia Drugs Product and Service

    • Table BioMarin (Foundation Year, Company Profile and etc.)

    • Table BioMarin Hemophilia Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table BioMarin Hemophilia Drugs Product and Service

    • Table Octapharma (Foundation Year, Company Profile and etc.)

    • Table Octapharma Hemophilia Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Octapharma Hemophilia Drugs Product and Service

    • Table Bayer (Foundation Year, Company Profile and etc.)

    • Table Bayer Hemophilia Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Bayer Hemophilia Drugs Product and Service

    • Table Swedish Orphan Biovitrum (Foundation Year, Company Profile and etc.)

    • Table Swedish Orphan Biovitrum Hemophilia Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Swedish Orphan Biovitrum Hemophilia Drugs Product and Service

    • Table Baxalta (Foundation Year, Company Profile and etc.)

    • Table Baxalta Hemophilia Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Baxalta Hemophilia Drugs Product and Service

    • Table Pfizer (Foundation Year, Company Profile and etc.)

    • Table Pfizer Hemophilia Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Pfizer Hemophilia Drugs Product and Service

    • Table Spark Therapeutics (Foundation Year, Company Profile and etc.)

    • Table Spark Therapeutics Hemophilia Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Spark Therapeutics Hemophilia Drugs Product and Service

    • Table CSL Behring (Foundation Year, Company Profile and etc.)

    • Table CSL Behring Hemophilia Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table CSL Behring Hemophilia Drugs Product and Service


Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US